Home/Filings/4/0000950170-24-106387
4//SEC Filing

Janku Filip 4

Accession 0000950170-24-106387

CIK 0001826457other

Filed

Sep 12, 8:00 PM ET

Accepted

Sep 13, 4:30 PM ET

Size

5.6 KB

Accession

0000950170-24-106387

Insider Transaction Report

Form 4
Period: 2024-09-13
Janku Filip
Chief Medical Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2024-09-13+30,00030,000 total
    Exercise: $7.56Exp: 2032-10-04Common Stock (30,000 underlying)
Footnotes (2)
  • [F1]On October 3, 2022, the Reporting Person was granted an option to purchase 30,000 shares of Common Stock, subject to the satisfaction of certain performance criteria. On September 13, 2024, the performance criteria underlying such shares were met.
  • [F2]The shares underlying this option shall vest in full on March 13, 2026, subject to the Reporting Person's continued service on such date.

Documents

1 file

Issuer

Monte Rosa Therapeutics, Inc.

CIK 0001826457

Entity typeother

Related Parties

1
  • filerCIK 0001862930

Filing Metadata

Form type
4
Filed
Sep 12, 8:00 PM ET
Accepted
Sep 13, 4:30 PM ET
Size
5.6 KB